Arvinas Inc. (ARVN) PT Lowered to $20 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
BTIG Reiterates Buy Rating on Arvinas Inc. (ARVN)
March 12, 2025 5:28 AM EDTBTIG analyst Jeet Mukherjee reiterated a Buy rating and $69.00 price target on Arvinas Inc. (NASDAQ: ARVN).
The analyst comments "Today, ARVN and partner Pfizer (PFE, NR) reported topline data from the Ph 3 VERITAC-2 trial in ER+/HER2- breast cancer. The study... More
Arvinas Inc. (ARVN) PT Lowered to $10 at Citi
March 11, 2025 3:52 PM EDTCiti analyst Yigal Nochomovitz lowered the price target on Arvinas Inc. (NASDAQ: ARVN) to $10.00 (from $19.00) while maintaining a Neutral rating.
The analyst comments "The failure of VERITAC-2 to meet the primary PFS endpoint in the ITT population, driven by the lack of... More
Oppenheimer Downgrades Arvinas Inc. (ARVN) to Perform
March 11, 2025 10:13 AM EDTOppenheimer analyst Matthew Biegler downgraded Arvinas Inc. (NASDAQ: ARVN) from Outperform to Perform.
The analyst comments "Arvinas shares are down sharply today (to ~$9.22) after the company announced that VERITAC-2 had missed on the all-comers co-primary endpoint. The ESR1-mutant co-primary endpoint... More
Arvinas Inc. (ARVN) and Pfizer (PFE) Announce Positive Topline Results from Phase 3 VERITAC-2 Trial
March 11, 2025 6:46 AM EDTArvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. These are the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC) ER degrader.
The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m)... More
